Repare Therapeutics Q1 2023 Earnings Report
Key Takeaways
Repare Therapeutics reported financial results for the first quarter ended March 31, 2023. The company continues to execute clinically and across pipeline programs, including presenting initial clinical data of camonsertib in combination with various PARP inhibitors from the ongoing TRESR and ATTACC trials. They are on track to present initial Phase 1 monotherapy data for RP-6306 in June.
Presented initial clinical data of camonsertib in combination with PARP inhibitors at AACR conference.
Camonsertib combination therapy showed 48% CBR across tumor types.
On track to report initial RP-6306 monotherapy data from Phase 1 MYTHIC clinical trial in June 2023.
Appointed Susan Molineaux, Ph.D. to Board of Directors and added Daniel Belanger to senior leadership team.
Repare Therapeutics
Repare Therapeutics
Forward Guidance
Repare expects to report initial Phase 1 monotherapy clinical data for RP-6306 for the treatment of molecularly selected advanced solid tumors (MYTHIC) in June 2023. The Company expects to report initial Phase 1 combination therapy clinical data for RP-6306 for the treatment of molecularly selected advanced solid tumors in the fourth quarter of the year.
Positive Outlook
- Present initial Phase 1 monotherapy data for RP-6306 in June 2023
- Report initial Phase 1 combination therapy clinical data for RP-6306 in the fourth quarter of the year
- Initiate clinical testing of RP-6306 combination with carboplatin
- Evaluate RP-6306 in patients with selected, advanced cancers receiving standard agents
- Advance preclinical programs into clinical development
Challenges Ahead
- Evolving impact of macroeconomic events on the Company’s business
- Unexpected safety or efficacy data observed during preclinical studies or clinical trials
- Clinical trial site activation or enrollment rates that are lower than expected
- Changes in expected or existing competition
- Changes in the regulatory environment